CJC-1295 + DAC

CJC-1295 + DAC (Drug Affinity Complex) is a synthetic growth hormone-releasing hormone (GHRH) analogue engineered for extended half-life and sustained receptor activity. By conjugating CJC-1295 with a Drug Affinity Complex, the peptide binds to albumin in the bloodstream, dramatically prolonging its active duration compared to unmodified GHRH analogues. This makes it one of the most studied compounds for investigating sustained growth hormone secretion, IGF-1 modulation, and anabolic signaling pathways in research settings.

GHRH analogue with DAC technology — albumin-binding complex for extended half-life and sustained receptor engagement
Growth hormone secretion — studied for stimulating pulsatile GH release and IGF-1 elevation
Extended activity window — DAC conjugation prolongs active duration vs. unmodified CJC-1295
≥99% purity — HPLC-verified, every batch
Flexible dosing — CD2 & CD5, matched to your protocol

Main Benefits:

• Sustained GH secretion — albumin binding extends active half-life for prolonged research windows
• IGF-1 modulation — studied for downstream anabolic signaling and tissue growth pathways
• Investigated for muscle protein synthesis and body composition research models
• Supports fat metabolism research via GH-mediated lipolysis pathways
• Lyophilized format — stable, consistent reconstitution and extended shelf life

For Research Use Only.